看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
. G( r0 K/ F: Q3 b. H0 v
% ]* p+ l2 X2 q1 E3 l$ }
- x, ]! k+ V9 l6 G, T2 q6 {Currently available feasibility data for possible combination strategies.
' M6 e% g) y+ v& Q7 W8 f————————————————————————————————
C3 `# T/ S4 KCombination Feasibility according to preliminary data
8 w) N+ C) J8 }0 S+ v3 m* m& t——————————————————————————————————
6 b* o) J3 T9 [Bevacizumab + sorafenib Yes, reduced dose
% I; a$ Y6 k8 s4 G( JBevacizumab + sunitinib† No
+ r5 ^" X. E% j- O( Z/ C3 {Bevacizumab + temsirolimus Yes 7 R7 ]* c) j6 }9 z* p
Bevacizumab + everolimus Yes ; N* b1 Z& ]# J! l" U1 Q; X
Sorafenib + sunitinib ?
$ x* A" \7 [6 A! L1 uSorafenib + temsirolimus Yes, reduced dose + E4 A7 c& U0 ^
Sorafenib + everolimus Yes, reduced dose
9 u3 h/ ?+ O5 x8 c- P( j% J: a( USunitinib + temsirolimus† No # O7 Y. x" ?3 _, H; F5 E
Sunitinib + everolimus ?
$ R, E, o. U, s# ATemsirolimus + everolimus ?
0 |+ D7 X4 w d1 U" H————————————————————
3 e, i Z- K M. d( X( N/ }†Led to US FDA warning.' j; ]# l* S& o# t1 B
?: As yet unattempted combination.0 d/ Z4 ^& c4 o: j
|
显身卡
